October 9th 2024
OncLive and the Ruesch Center for the Cure of GI Cancers announce the winners of the 2024 Luminary Awards in GI Cancers.
January 14th 2022
The types of conversations that breast oncologists should have with their patients with breast cancer before initiating T-DM1, and recommendations for managing treatment-related adverse events.
Marcia Brose, MD, PhD, FASCO, explains how she counsels and monitors patients with differentiated thyroid cancer and indicators to initiate therapy.
Impressions regarding the management of a 62-year-old woman with HER2-postive breast cancer who received adjuvant T-DM1 treatment following neoadjuvant TCHP and has signs of residual disease.
The pros and cons of thyrotropin suppression as treatment for patients with differentiated thyroid cancer.
January 7th 2022
Criteria used by endocrinologists/oncologists to establish goals of therapy for patients with differentiated thyroid cancer, and recommendations for active surveillance.
An overview of antibody-drug conjugate therapies available for patients with metastatic breast cancer and triple-negative breast cancer based on outcomes demonstrated in clinical trials.
Marcia Brose, MD, PhD, FASCO, and Maria E. Cabanillas, MD, compare the use of molecular testing for radioactive iodine-refractory differentiated thyroid cancer at their institutions and highlight predictive and prognostic biomarkers.
December 23rd 2021
Allison Butts, PharmD, BCOP, describes what antibody-drug conjugates are and explains the role in metastatic breast cancer treatment.
December 22nd 2021
Exciting therapeutic strategies in the HER2-positive metastatic breast cancer space that demonstrate potential in addressing gaps in treatment.
A small panel of breast oncologists recognize growing interest in understanding the role of HER2 expression in metastatic breast cancer.
Expectations regarding future treatment guidelines in HER2-positive metastatic breast cancer as a result of therapeutic advances.
December 17th 2021
The typical diagnostic work-up for patients with advanced differentiated thyroid cancer, the rationale for treating patients with radioactive iodine (RAI), and a definition of RAI-refractory disease.
Signs and symptoms of differentiated thyroid cancer and recommendations for establishing an accurate diagnosis.
Naifa L. Busaidy, MD, FACP, FACE, comments on risk factors associated with the subtypes of thyroid cancers.
Giuseppe Barbesino, MD, highlights the various types of thyroid cancers and comments on how their differences impact management.
December 15th 2021
Variables that affect second-line treatment decisions in HER2-positive metastatic breast cancer.
Recommendations regarding how to best treat a patient with HER2-positive metastatic breast cancer who has previously received multiple lines of therapy, including T-DM1.
December 6th 2021
Reactions to presentations from ESMO 2021 that demonstrated the potential of various new treatment approaches for use in HER2-positive metastatic breast cancer.
Key takeaways from updates to the HER2CLIMB study in HER2-positive metastatic breast cancer.